Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

02-012024

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis

Guangzhou, China -- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline o...
01-032024

Bio-Thera Solutions Partners with Macter International to Market BAT1706, an Avastin®1 biosimilar, in Pakistan and Afghanistan

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline ...
12-082023

FDA Approves Bio-Thera Solutions’ Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®

Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United StatesAvzivi® is the second biosimilar...

上一页 ···12 13 14 15 16 ··· 下一页